Boehringer Ingelheim International GmbH
The Boehringer Ingelheim (BI) group is one of the world’s 20 leading pharmaceutical companies. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Around 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. Immunology represents one of the key Therapeutic Areas (TA) pursued within the One Human Pharma business. BI scientists work with an extensive network of external partners to discover and develop transformative therapies to address unmet medical needs associated with chronic inflammatory skin diseases such as atopic dermatitis and psoriasis. Risankizumab, an IL23p19 selective antibody was first discovered at BI and is now partnered with Abbvie. BI 655130, an anti-IL36R selective antibody is currently in advanced stage clinical studies for the treatment of several skin diseases, including generalized pustular psoriasis. In addition, several other large and small molecules are also being progressed in the dermatology area as well.
Role within BIOMAP
Within BIOMAP, BI team with the extensive experience in bioinformatics field will provide insights into the analysis of data. In addition, due to BI team’s knowledge and expertise in understanding tissue based pathways in cellular immunology and integrating data from various platforms such as FACS, RNA seq and single cell RNA seq, BI will also support work packages focused on these aspect by funding post-docs. With the expertise of its team in biomarkers implementation, pathway analysis in clinical trials across multiple disease indications, BI team will also support efforts focused on this aspect within the BIOMAP consortium.